LICA Collaborates with Cold Spring Harbor Laboratory and TheFeinstein Institute for Medical Research on the EventMelville, NY – May 1, 2014 – The Long Island Capital Alliance (“LICA”), the leading non-profit capital formation and business development organization serving regional companies, today announced the presenting companies and panelists for its Biotech Capital Forum to be held on Friday, May 9, 2014. The capital forum is being held in collaboration with North Shore-LIJ Health System’s Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory in an effort to facilitate raising capital to accelerate the growth of biotech businesses on Long Island.
Seven local biotechnology companies will present their business plans to investors, including attendees from venture capital firms, investment banks, private equity firms, angel and other individual investors. Each of the companies LICA selected for presentation at the capital forum possesses unique technologies and catalysts for significant growth which will be attractive to investors.
“We are pleased to be collaborating for a second time with Cold Spring Harbor Laboratory and welcome The Feinstein Institute for Medical Research in participating in our Biotech Capital Forum,” said Neil Kaufman, Chairman of LICA. “These two world-class research institutions have developed seven very promising companies which will present at our Biotech Capital Forum. The volume and magnitude of research being conducted there continues to produce compelling growth companies, enabling LICA to present its Biotech Capital Forum for the second consecutive year, and we hope to continue to do so annually. We are also excited to have an extraordinarily accomplished investor panel provide their insight on these presenting companies and on biotech industry investment trends.”
Biotech Capital Forum on May 9, 2014 – ParticipantsPanel of Investors
The following investment professionals will participate in the investor panel at the Biotech Capital Forum:
Doug Jamison, Harris & Harris Group: Doug Jamison is Chairman and Chief Executive Officer of Harris & Harris Group (NASDAQ: TINY), a leading early stage biotech investment fund. He is a member of the Board of Directors of Ancora Pharmaceuticals, Inc., and a Board observer in ABS Materials, Inc., Mersana Therapeutics, Inc., Solazyme, Inc., Nextreme Thermal Solutions, Inc., and Metabolon, Inc.
James Ryan III, Scout Ventures: James Ryan is Controller at Scout Ventures, a technology seed and venture fund. In addition, he is the Founder and CEO of The IllumiFi Group, an ‘Outsourced CFO’ for entrepreneurial firms.
Joe Proto, Windham Venture Partners: Joe Proto is a founder and general partner of Windham Venture Partners, a leading life sciences technology venture capital firm. He also is Chairman and Chief Executive Officer of Transactis Inc., sits on the Board of Directors of BillMyParents, and is a limited partner and advisor in Metamorphic Ventures.
Steve Winick, Topspin Partners: Steve Winick is a principal of Topspin Partners, one of Long Island’s leading venture capital firms. He presently serves as a Director of Thermolift, Inc., Celmatix, Inc., Setpoint Medical, Inc., Mirimus, Inc., GenDX, Inc. and Certerra, Inc.
Presenting CompaniesASOThera: Developing new therapies for orphan diseases based on technology developed at Cold Spring Harbor Laboratory and already proven by Big Pharma.
Autoimmune Therapeutics, Inc.: Developing orally-available drug candidates to treat autoimmune disease, with initial focus on rheumatoid arthritis, based on proprietary small molecule scaffolds and pharmaceutical leads that inhibit macrophage migration inhibitory factor.
Certerra, Inc.: Contract research organization specializing in central nervous system with technology based on single neuron-level monitoring of mammalian brains.
Cirrus Health: Electronic discharge system to improve doctor patient communications.
DepYMed: Joint venture between CSHL and Ohr Pharmaceuticals (NASDAQ: OHRP) to develop a drug for obesity, diabetes and HER2 cancer based on trodusquemine and related analogs.
Envisagenics, Inc.: Big data software solution that significantly reduces uncertainty and time to market for drugs under development.
TheraSource, LLC: Developing protein/peptide-based drugs based on MFG-E8 for inflammatory diseases, including sepsis, hemorrhagic shock, ischemia/reperfusion-induced injury, stroke, acute radiation syndrome, rheumatoid arthritis, and inflammatory bowel disease.
LICA, in collaboration with The Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory, is hosting the Biotech Capital Forum on Friday, May 9, 2014 from 8:00 a.m. to 11:00 a.m. at 68 South Service Road, Melville, NY. The capital forum provides an opportunity to meet capital providers, entrepreneurs, industry executives and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for bio tech companies.
For more information about the event, please contact LICA today or register online.
Originally published on licapital.org.